Skip to main content
Livermore
Livermore
ZHEN

Perceptive Advisors LLC

SEC CIK
0001224962
Latest filing
Aug 14, 2026

Holdings in Q4 2021

Holdings as of Dec 31, 2021, filed May 4, 2022. Long positions only; changes compare share counts with Q3 2021.

Institution overview
Positions
145
+7 vs. Q3 2021
Portfolio value
$6.47B
−$388.8M (−5.7%) vs. Q3 2021
Filed
May 4, 2022
AmendedSEC
Holdings of Perceptive Advisors LLC in Q4 2021
SecurityClassSharesValue% of portfolioShare changeActionHistory
ISOIsoPlexis CorpCOM4,095,498$37.6M0.6%+4,095,498NewHistory
OMICSingular Genomics Systems, Inc.COM3,333,824$38.5M0.6%+260,000+8.5%AddedHistory
ALDXAldeyra Therapeutics, Inc.COM9,903,879$39.6M0.6%00.0%UnchangedHistory
MORFMorphic Holding, Inc.COM836,521$39.6M0.6%−50,819−5.7%ReducedHistory
NBIXNeurocrine Biosciences IncStock483,007$41.1M0.6%00.0%UnchangedHistory
QTNTQuotient LtdSHS16,200,818$42.0M0.6%00.0%UnchangedHistory
RCKTRocket Pharmaceuticals, Inc.COM1,959,125$42.8M0.7%−351,136−15.2%ReducedHistory
ICVXIcosavax, Inc.COM1,906,548$43.6M0.7%−16,001−0.8%ReducedHistory
KODKodiak Sciences Inc.COM520,152$44.1M0.7%+58,904+12.8%AddedHistory
LONALeonaBio, Inc.COM3,425,916$44.6M0.7%00.0%UnchangedHistory
ARNAArena Pharmaceuticals IncCOM NEW500,000$46.5M0.7%+500,000NewHistory
NAUTNautilus Biotechnology, Inc.COM9,111,151$47.2M0.7%+200,000+2.2%AddedHistory
Coherus Biosciences Inc19249HAB9NOTE 1.500% 4/1–$51.5M0.8%–––
ChemoCentryx, Inc.16383L106COM1,415,446$51.5M0.8%+865,446+157.4%Added–
ALBOAlbireo Pharma, Inc.COM2,360,139$55.0M0.8%00.0%UnchangedHistory
TVTXTravere Therapeutics, Inc.COM1,845,555$57.3M0.9%−120,000−6.1%ReducedHistory
INBXInhibrx Biosciences, Inc.COM1,343,490$58.7M0.9%+222,000+19.8%AddedHistory
RLAYRelay Therapeutics, Inc.COM1,943,097$59.7M0.9%00.0%UnchangedHistory
ZYMEZymeworks Inc.COM3,679,845$60.3M0.9%00.0%UnchangedHistory
Bellus Health Inc New07987C204COM NEW7,645,234$61.5M1.0%+7,645,234New–
APLSApellis Pharmaceuticals, Inc.COM1,451,700$68.6M1.1%+836,700+136.0%AddedHistory
CCCCC4 Therapeutics, Inc.COM STK2,208,913$71.1M1.1%−49,653−2.2%ReducedHistory
LABPLandos Biopharma, Inc.COM14,869,915$71.4M1.1%00.0%UnchangedHistory
XENEXenon Pharmaceuticals Inc.COM2,411,447$75.3M1.2%+389,396+19.3%AddedHistory
OMOutset Medical, Inc.COM1,863,397$85.9M1.3%−127,236−6.4%ReducedHistory
CHRSCoherus Oncology, Inc.COM5,407,798$86.3M1.3%+628,411+13.1%AddedHistory
GBTGlobal Blood Therapeutics, Inc.COM3,449,915$101.0M1.6%−957,484−21.7%ReducedHistory
Nevro Corp64157FAC7NOTE 2.750% 4/0–$101.5M1.6%–––
BMRNBiomarin Pharmaceutical IncCOM1,180,000$104.3M1.6%+1,180,000NewHistory
RAPTRAPT Therapeutics, Inc.COM2,927,565$107.5M1.7%+20,000+0.7%AddedHistory
ISEEIVERIC bio, Inc.COM6,480,000$108.3M1.7%−991,798−13.3%ReducedHistory
BBIOBridgeBio Pharma, Inc.COM7,128,755$118.9M1.8%−628,173−8.1%ReducedHistory
VBIVVBI Vaccines Inc/BCCOM NEW52,335,002$122.5M1.9%−2,707,463−4.9%ReducedHistory
RXDXPrometheus Biosciences, Inc.COM3,172,785$125.5M1.9%−141,247−4.3%ReducedHistory
CRNXCrinetics Pharmaceuticals, Inc.COM5,163,517$146.7M2.3%+1,200,000+30.3%AddedHistory
CERECerevel Therapeutics Holdings, Inc.COM5,086,727$164.9M2.5%00.0%UnchangedHistory
MGTXMeiraGTx Holdings plcCOM6,948,277$165.0M2.5%00.0%UnchangedHistory
Collegium Pharmaceutical, Inc19459JAA2NOTE 2.625% 2/1–$169.3M2.6%–––
HZNPHorizon Therapeutics Public Ltd CoSHS1,738,140$187.3M2.9%−218,800−11.2%ReducedHistory
IOVAIovance Biotherapeutics, Inc.COM10,127,941$193.3M3.0%−1,361,831−11.9%ReducedHistory
SWTXSpringWorks Therapeutics, Inc.COM4,849,912$300.6M4.6%00.0%UnchangedHistory
FOLDAmicus Therapeutics, Inc.COM26,559,443$306.8M4.7%00.0%UnchangedHistory
LIANYLianBioSPONSORED ADS56,319,960$346.9M5.4%+56,319,960NewHistory
MRTXMirati Therapeutics, Inc.COM3,283,783$481.7M7.4%−103,962−3.1%ReducedHistory
Retrophin Inc761299AB2NOTE 2.500% 9/1–$484.7M7.5%–––

Options (2)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Perceptive Advisors LLC in Q4 2021
SecurityClassPutsCalls
FLNAFilana Therapeutics, Inc.COM$13.1M–
DCPHDeciphera Pharmaceuticals, Inc.COM–$1.95M

Sold out since Q3 2021 (15)

Positions held at the end of Q3 2021 that are gone from this filing.

Positions of Perceptive Advisors LLC sold out since Q3 2021
SecurityClassShares in Q3 2021Value in Q3 2021% of portfolio in Q3 2021History
AVIRAtea Pharmaceuticals, Inc.COM2,259,224$79.2M1.2%History
BEAMBeam Therapeutics Inc.COM537,635$46.8M0.7%History
DBVTDBV Technologies S.A.SPONSORED ADR7,695,505$37.7M0.5%History
Avidity Biosciences, Inc.05370A108COM885,818$21.8M0.3%–
NTRANatera, Inc.COM160,000$17.8M0.3%History
CM Life Sciences III Inc125841205UNIT 04/30/20281,250,000$12.8M0.2%–
PODDInsulet CorpStock44,522$12.7M0.2%History
FDMT4D Molecular Therapeutics, Inc.COM375,256$10.1M0.1%History
TSHATaysha Gene Therapies, Inc.COM SHS320,440$5.97M0.1%History
PSTXPoseida Therapeutics, Inc.COM787,745$5.74M0.1%History
ATECAlphatec Holdings, Inc.COM NEW430,900$5.25M0.1%History
RGNXREGENXBIO Inc.COM89,283$3.74M0.1%History
SNCEScience 37 Holdings, Inc.COM300,000$2.94M<0.1%History
IMGOImago BioSciences, Inc.COM125,000$2.50M<0.1%History
KRROKorro Bio, Inc.COM222,222$1.57M<0.1%History